Melatonin: Benefits, Forms, Dosing, and Side Effects

Melatonin is a hormone produced by the pineal gland in response to darkness, serving as the body's primary circadian rhythm signal. It plays roles in sleep-wake regulation, antioxidant defense, immune modulation, and gastrointestinal function. Supplemental melatonin is supported by evidence for jet lag, delayed sleep-wake phase disorder, pre-surgical anxiety, and some pediatric sleep disorders, though major guidelines favor cognitive behavioral therapy (CBT-I) over melatonin for chronic insomnia.

Only about 15% of oral melatonin reaches the bloodstream due to extensive first-pass liver metabolism, though individual bioavailability ranges from 1% to 74%. Small to moderate doses do not suppress the body's own melatonin production, and discontinuation does not cause rebound insomnia or withdrawal [14][15].

Table of Contents

• Overview
• Forms and Bioavailability
• Evidence for Benefits
• Recommended Dosing
• Safety and Side Effects
• Drug Interactions
• Dietary Sources
• References

Overview

Melatonin (N-acetyl-5-methoxytryptamine) is a hormone produced primarily by the pineal gland in the brain from the amino acid tryptophan, with serotonin as an intermediate in the biosynthetic pathway [1][2]. Secretion follows a robust circadian rhythm: levels are low during the day and rise sharply in the evening in response to darkness, typically peaking between 2:00 and 4:00 a.m., before declining toward morning [2][3]. This rhythmic pattern is regulated by the suprachiasmatic nucleus (SCN) of the hypothalamus, the body's master circadian clock, which receives light-dark signals from the retina [2]. Melatonin binds to high-affinity G-protein-coupled receptors MT1 and MT2 in the SCN, where MT1 activation inhibits neuronal firing and MT2 mediates phase shifts of the circadian clock [2][4].

Although the pineal gland is the primary source of circulating melatonin, smaller amounts are also synthesized in extrapineal tissues including the retina, gastrointestinal tract (where melatonin concentrations are 10-100 times higher than in the blood), and immune cells [2][5]. Gastrointestinal melatonin production is notable because it is not governed by photoperiod but appears to be related to food intake [5].

Beyond sleep-wake regulation, melatonin possesses potent antioxidant properties, acting as a direct free radical scavenger to protect cells from oxidative damage [2][6]. It also modulates immune function by influencing cytokine production, enhancing natural killer cell activity, and supporting immune homeostasis [2][7].

Factors that decrease endogenous melatonin production include exposure to light at night (even dim light can suppress production) [8], certain medications such as benzodiazepines (e.g., diazepam) [9], beta-blocker drugs (which suppress nocturnal melatonin release) [10], and caffeinated coffee consumed in the afternoon or evening [11]. Interestingly, cataract removal with clear intraocular lenses has been shown to significantly increase natural melatonin production, likely by restoring nonvisual light perception and improving circadian alignment (Nishi, JAMA Ophthalmol 2020) [12].

The melatonin in dietary supplements is generally manufactured synthetically or extracted from plants, and both forms are chemically identical to endogenous melatonin [1]. In the United States, melatonin is classified as a dietary supplement and regulated less strictly than prescription drugs. In contrast, melatonin is available only by prescription in many other countries including the United Kingdom, Australia, and much of the European Union [1][13].

Taking small to moderate doses of melatonin does not appear to decrease the body's own melatonin production. A placebo-controlled study found that 0.5 mg of melatonin taken every evening for seven days did not suppress endogenous production (Matsumoto, J Pineal Res 1997) [14]. A longer study in Israel found that 2 mg of prolonged-release melatonin taken daily for 6-12 months did not cause "rebound" insomnia or withdrawal symptoms, and endogenous melatonin levels (measured by urinary metabolite 6-sulfatoxymelatonin) were within normal ranges two weeks after discontinuation (Lemoine, Ther Clin Risk Manag 2011) [15].

Forms and Bioavailability

Oral Formulations

Melatonin supplements come in several delivery forms:

• Regular tablets, capsules, and softgels -- Act within 30-60 minutes of ingestion. Suitable for sleep onset difficulties.
• Fast-dissolving (sublingual) tablets -- Can be taken approximately 20 minutes before desired sleep. May be absorbed partially through oral mucosa, though published research has not demonstrated superior bioavailability compared to swallowed forms (Zetner, Drug Res (Stuttg) 2016) [16].
• Liquid formulations -- Allow precise dose adjustments in small increments; particularly useful for children.
• Gummies -- Comparable onset to fast-dissolving tablets when well chewed, but contain sugars and should be followed by dental hygiene.
• Timed-release (extended-release, controlled-release) -- Sustain blood levels of melatonin for a longer period, potentially helping with sleep maintenance rather than just sleep onset.
• Topical lotions and creams -- Marketed for sleep but with limited evidence of efficacy (see below).

Absorption and First-Pass Metabolism

Melatonin is both fat- and water-soluble, so it can be taken with or without food [1][17]. Once absorbed from the gastrointestinal tract, melatonin undergoes extensive first-pass metabolism in the liver, primarily via the cytochrome P450 enzyme CYP1A2 [2][17]. As a result, only approximately 15% of orally ingested melatonin reaches systemic circulation, although this varies significantly between individuals -- reported bioavailability ranges from 1% to 74% (Di, N Engl J Med 1997; DeMuro, J Clin Pharmacol 2000; Andersen, BMC Pharmacol Toxicol 2016) [17][18][19]. Peak plasma concentrations are typically reached within 30-60 minutes, and the elimination half-life is approximately 45 minutes for immediate-release forms [2][17].

Timed-release formulations do not increase overall bioavailability but sustain elevated blood melatonin levels for a longer duration [1]. There is no convincing evidence at this time that one oral formulation (tablet, capsule, liquid, gummy) is superior to another for maximizing bioavailability [1].

Synthetic vs. Plant-Derived Melatonin

Most melatonin supplements are synthetic but chemically identical to endogenous melatonin [1]. Plant-based melatonin ("phytomelatonin") from sources like rice, alfalfa, chlorella, or St. John's wort is generally more expensive. A test-tube study indicated that one plant-derived product (Herbatonin) had stronger antioxidant and anti-inflammatory activity than synthetic melatonin, possibly due to other plant constituents, but whether this translates into clinical benefit in humans is unknown (Kukula-Koch, Molecules 2021) [20]. There is no clinical evidence that plant-derived melatonin is more effective than synthetic melatonin for sleep or any other outcome [1].

Melatonin extracted from animal glands carries a theoretical concern for prion transmission (bovine spongiform encephalopathy), though no such transmission from supplements has been documented [1].

Topical Melatonin

A study of 36 healthy young adults found that applying 7 grams of melatonin lotion to the hands and arms one hour before bedtime did not significantly improve sleep compared to placebo, despite increasing salivary melatonin levels up to 1,000-fold at 30 minutes post-application. A subgroup of 18 poor sleepers showed a slight improvement (1.5 points on a 14-point scale) that was statistically significant (Ponce, Neuro Endocrinol Lett 2024) [21]. Overall, evidence for topical melatonin as a sleep aid is limited.

Evidence for Benefits

Insomnia and General Sleep Improvement in Adults

The evidence for melatonin in chronic insomnia is modest. The American Academy of Sleep Medicine (2017) and the American College of Physicians (2016) concluded that evidence is insufficient to recommend melatonin for chronic insomnia, strongly recommending cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment [13][22].

That said, several studies show melatonin can help with specific aspects of sleep:

Primary insomnia: A study among 97 middle-aged adults (average age 57) with primary insomnia found that 3 mg of fast-release melatonin taken one hour before bedtime for 4 weeks decreased the percentage of time in non-REM sleep (light sleep) and reduced early waking by 30 minutes compared to placebo, as measured by polysomnography. However, melatonin did not shorten time to fall asleep, increase total sleep time, reduce nighttime wakening, or improve self-reported sleep quality (Xu, Sleep Med 2020) [23].

Obstructive sleep apnea with insomnia: A study of 30 adults (average age 59) with moderate to severe obstructive sleep apnea requiring CPAP found that 10 mg of melatonin taken 30-60 minutes before sleep for one month improved sleep quality by 6.53 points (0-21 scale), reduced insomnia severity by 6.53 points (0-28 scale), reduced daytime sleepiness by 6.47 points (0-24 scale), and improved daytime function by 5.06 points (10-40 scale) compared to placebo. CPAP compliance also improved (Motlaq, J Pharm Health Care Sci 2024) [24].

REM sleep behavior disorder: A study found that 2 mg or 6 mg of prolonged-release melatonin taken 30 minutes before bedtime for one month did not reduce the frequency or severity of REM sleep behavior disorder episodes or improve sleep quality compared to placebo (Jun, Ann Clin Transl Neurol 2019) [25].

Parkinson's disease: Melatonin may improve sleep in Parkinson's disease patients, who often have decreased endogenous melatonin production. A study of 34 patients found that 2 mg of prolonged-release melatonin taken one hour before bedtime for one month improved self-reported sleep quality, particularly time to fall asleep and sleep disturbances, but not motor symptoms, compared to placebo (Ahn, Parkinsonism Relat Disord 2020) [26]. Earlier studies confirmed similar findings (Mack, Oxid Med Cell Longev 2017; Medeiros, J Neurol 2007) [27][28].

Tinnitus: A study found that 3 mg of melatonin daily for one month produced a 40% reduction in perception of tinnitus versus 22% with placebo. Those taking both melatonin and the drug sulpiride had an 81% reduction, suggesting melatonin may enhance drug effects (Lopez-Gonzalez, J Otolaryngol 2007) [29]. However, due to small study sizes and evidence quality concerns, some experts recommend against melatonin for persistent tinnitus due to a greater risk of harm than benefit (Tunkel, Otolaryngol Head Neck Surg 2014) [30].

Glaucoma: A study of 64 adults (average age 66) with advanced primary open-angle glaucoma found that 5 mg of melatonin daily for 30 days did not improve self-reported sleep quality, increase sleep time, or reduce waking compared to placebo (Nogueira, Ophthalmol Glaucoma 2025) [31].

Melatonin tolerance: Some people experience loss of response to melatonin after initially showing improvements. Clinical evidence suggests this may relate to slow metabolism of melatonin, resulting in high daily levels that blunt the normal circadian rhythm. In such cases, lowering the dose (e.g., from 1-5 mg to 0.1-0.5 mg) may actually restore response (Braam, J Intellect Disabil Res 2010) [32].

Delayed Sleep Phase Syndrome (DSPS)

DSPS is a condition in which people cannot fall asleep until early morning, possibly due to delayed melatonin release. In 2015, the American Academy of Sleep Medicine recommended melatonin for DSPS, though the recommendation was weak due to uncertainty about whether benefits outweigh harms [22].

A study of 104 adults with DSPS found that 0.5 mg of fast-release melatonin taken one hour before desired bedtime for one month resulted in falling asleep 34 minutes earlier, with significant decreases in self-reported sleep disturbance, insomnia severity, and interference with daily life compared to placebo. However, the treatment did not appear to correct the underlying condition -- there was no increase in natural melatonin production around the desired bedtime by end of study (Sletten, PLoS Med 2018) [33].

A 2016 review of 2 studies (52 participants) found melatonin reduced time to fall asleep by about 22 minutes in DSPS patients [22]. For delayed weekend sleep pattern, 6 mg taken five hours before desired Sunday bedtime has been used [1].

Jet Lag

Four studies (total n=142 travelers) showed melatonin may reduce overall symptoms of jet lag after eastward flights. A study of 234 travelers found low-quality evidence of improved sleep quality on eastward flights. Two studies (n=90) showed benefit after westward flights [13][34]. The typical dose used is 2-3 mg taken at bedtime at the destination for four days following travel.

Shift Work

Evidence is generally small and inconclusive [13]. One review of 7 studies (n=263) suggested melatonin may increase daytime sleep duration by about 24 minutes in shift workers, but other sleep aspects did not improve. Another review of 8 studies (n=300) had inconclusive results and made no recommendations [13][35].

A study of young doctors and nurses found that 6 mg of slow-release melatonin before morning sleep modestly improved concentration and attention before and after nightshifts, though no measures of sleep improved (Thottakam, Front Psychiatry 2020) [36]. Another study of 27 overweight female night-shift nurses found that 3 mg of melatonin one hour before bedtime on days off for 12 weeks reduced sleep rhythm misalignment by about 20% and produced very slight reductions in bodyweight, BMI, and waist and hip circumference in early chronotypes (Marqueze, J Pineal Res 2021) [37].

Sleep in Children and Adolescents

The American Academy of Sleep Medicine (AASM) advises parents to talk to a healthcare professional before giving melatonin to children, noting an overall lack of evidence of benefit and safety concerns, including reports of overdose. AASM recommends that parents focus on good sleep habits rather than melatonin supplementation [38].

A 2019 review of 18 studies (n=1,021 children) found melatonin was better than placebo for improving time to fall asleep and total sleep. Results by condition [13]:

• Autism spectrum disorder (ASD): Fell asleep 37 minutes earlier, slept 48 minutes longer
• ADHD: Fell asleep 20 minutes earlier, slept 33 minutes longer
• Atopic dermatitis: Fell asleep 6.8 minutes earlier, slept 35 minutes longer
• Chronic sleep-onset insomnia: Fell asleep 24 minutes earlier, slept 25 minutes longer

Children with chronic sleep onset insomnia: A study of 84 children (average age 10) found that 3 mg of melatonin at 7 PM for 3-4 weeks reduced time to fall asleep by about 16 minutes versus an 8-minute increase with placebo. Total sleep time increased by only 5 minutes due to increased waking after initially falling asleep, suggesting 3 mg may be too high -- researchers recommended trying 1 mg first (van Maanen, Sleep 2017) [39].

Children with ASD: A 3-month study of 95 children and adolescents with ASD or Smith-Magenis syndrome found that prolonged-release melatonin (2 mg, increased to 5 mg if needed) reduced time to fall asleep by 25 minutes and increased sleep duration by 32 minutes compared to placebo. Headache (13% vs. 6%) and daytime sleepiness (28% vs. 11%) were more common with melatonin (Gringras, J Am Acad Child Adolesc Psychiatry 2017) [40]. A 2-year follow-up of 74 participants found the most frequent adverse events were fatigue (6.3%), somnolence (6.3%), and mood swings (4.2%), but weight, height, BMI, and pubertal development remained within normal ranges (Malow, J Am Acad Child Adolesc Psychiatry 2020) [41].

A study of 169 Japanese children with ASD (ages 6-15) found that 1 mg and 4 mg of melatonin taken 45 minutes before bedtime for two weeks reduced time to fall asleep by 17 and 23 minutes, respectively, compared to placebo. The researchers recommended starting at 1 mg and increasing only if needed (Hayashi, J Autism Dev Disord 2021) [42].

A study of 62 children with ASD found that 3 mg of liquid melatonin 30 minutes before bedtime for 2 weeks improved sleep efficiency by about 8% and increased sleep duration by 30 minutes. Melatonin was about as effective as 60 minutes of cycling five times weekly, but combining the two did not have added benefit (Tse, J Autism Dev Disord 2023) [43].

Children with ADHD: A review of two studies found that 3-6 mg of melatonin daily for up to 4 weeks did not significantly improve behavior or quality of life, although it reduced time to fall asleep by 20 minutes and increased total sleep duration by 33 minutes (McDonagh, J Child Neurol 2019) [44].

Perioperative Use (Anxiety, Sedation, and Recovery)

Preoperative anxiety: A review of 27 clinical studies concluded that melatonin taken 1-1.5 hours before surgery reduces preoperative anxiety compared to placebo, and in some cases as well as benzodiazepine medications such as midazolam. Doses ranged from 3-10 mg. Few adverse events were reported, with mild nausea, sleepiness, dizziness, and headache occasionally noted (Madsen, Cochrane Database Syst Rev 2020) [45]. In children under 14, 0.5-5 mg (0.5 mg/kg) taken 30 minutes before a blood draw significantly reduced anxiety and pain compared to placebo (Marseglia, J Biol Regul Homeost Agents 2015) [46]. The NIH NCCIH's 2015 review of 12 studies (n=774) found strong evidence that melatonin reduces preoperative anxiety, with effectiveness possibly comparable to midazolam [13].

ICU sleep quality: A study of 203 ICU patients (average age 59) found that 10 mg of melatonin given 2 hours after dinner for up to 7 nights improved self-reported sleep quality -- 46% vs. 34% had "very good sleep" and 3% vs. 14% had "very poor sleep" compared to placebo. Melatonin did not reduce analgesic or sedative use or reduce pain, anxiety, or delirium (Gandolfi, Crit Care Med 2020) [47].

After surgery: Multiple studies show limited benefit. A study of 80 patients after rotator cuff repair found 5 mg of melatonin nightly for six weeks did not improve sleep quality, reduce pain, or improve function (Perez, Am J Sports Med 2024) [48]. A study of 118 patients after hip or knee replacement found 6 mg of melatonin did not improve sleep by 2 or 6 weeks (Clarkson, J Am Acad Orthop Surg 2021) [49]. A study of 128 patients after knee replacement found 5 mg nightly showed only a slight benefit during the first 3 nights with no overall benefit over 2 weeks (Haider, J Arthroplasty 2024) [50].

Post-operative delirium: A study of 166 cardiac surgery patients (average age 68) found that 3 mg of melatonin for seven consecutive nights (starting two nights before surgery) did not reduce delirium incidence, severity, or duration. However, subanalysis suggested it may have reduced risk in patients 75+ while possibly increasing risk in those with lowest cognitive performance scores (Ford, J Am Geriatr Soc 2019) [51].

Post-stroke delirium: Giving 2 mg of melatonin within 24 hours after ischemic stroke and continuing nightly until discharge reduced post-stroke delirium: 25.6% vs. 36.6% (Mengel, Eur J Neurol 2021) [52].

Headache and Migraine

Migraine: A placebo-controlled study of 178 patients found that 3 mg of melatonin daily for 3 months reduced migraine days from 7.3 to 4.6 per month versus 7.3 to 6.2 with placebo. The reduction was comparable to 25 mg of amitriptyline (7.2 to 5.0 days) but with fewer side effects, particularly no weight gain (Goncalves, J Neurol Neurosurg Psychiatry 2016) [53].

Primary stabbing headache (PSH): In adults, 3-12 mg of melatonin nightly for 2-4 months has been reported to eliminate episodes (Rozen, Neurology 2003) [54]. A case report of a 7-year-old boy with approximately 21 PSH episodes per month showed that 1.5 mg of melatonin nightly eliminated episodes within two weeks, with no recurrence during six months of supplementation (Salazar, Colomb Med (Cali) 2018) [55].

Cluster headache: 10 mg before bedtime daily has been used for prevention [1].

Menopause and Women's Health

Perimenopause: A 3-month study of 91 perimenopausal women (average age 49) found that 3 mg of melatonin taken every evening for three weeks per month improved sleep quality (5.6 points on a 22-point scale vs. no change with placebo) and climacteric symptoms including hot flashes, palpitations, and headache (15.5 vs. 3.5 points improvement). Melatonin also modestly improved mood and quality of life, and decreased luteinizing hormone and follicle-stimulating hormone levels (Zhang, J Healthc Eng 2023) [56].

Postmenopause -- symptom relief: A study of 60 postmenopausal women (ages 51-64) found that melatonin taken twice daily (3 mg morning + 5 mg bedtime) for one year reduced self-reported severity of sleep difficulty, hot flashes, sweating, heart palpitations, dizziness, irritability, and depressed mood. Average symptom severity decreased by 9 points (scale of 1-51) vs. 3 points with placebo. Three women reported increased morning fatigue during the first week (Chojnacki, J Physiol Pharmacol 2018) [57].

Postmenopause -- sleep quality at low dose: A study of 46 women at various menopause stages found that 0.3 mg of melatonin taken every other night for 3 months improved self-reported sleep quality by 35% on days off (though not on work days), but the improvement (~2.65 points on a 21-point scale) was slightly less than the clinically meaningful threshold of 3 points. Melatonin did not increase sleep duration (Saraiva, J Pineal Res 2026) [58].

Nocturia: A study of 60 postmenopausal women (average age 67) with nocturia found that 2 mg of melatonin one hour before bedtime for two weeks resulted in one fewer nighttime urination episode (1.3 vs. 2.3 episodes) and one hour more sleep before first waking compared to placebo. Interestingly, total sleep time decreased by about 30 minutes with melatonin, possibly because improved deep sleep quality reduced the need for longer sleep (Leerasiri, Int Urogynecol J 2022) [59].

Bone density in postmenopausal women: A placebo-controlled study found that 1 mg or 3 mg of melatonin nightly for one year, with calcium (800 mg) and vitamin D (800 IU), improved bone density. At 3 mg, femoral neck bone density increased by 2.3% and inner bone thickness in the tibia and lumbar spine increased by 2.2% and 3.6%, respectively. Melatonin prevented the increase in urinary calcium loss seen with calcium/vitamin D supplementation in the placebo group (Amstrup, J Pineal Res 2015) [60]. However, long-term melatonin use has been associated with increased fracture risk (see Safety section), and the clinical implications remain uncertain.

Polycystic ovary syndrome (PCOS): A small study found that 5 mg of melatonin twice daily for 12 weeks modestly reduced hirsutism and total testosterone, as well as biomarkers of inflammation and oxidative stress, compared to placebo (Jamilian, Front Endocrin 2019) [61].

Endometriosis pain: Mixed results. A study of 30 women found 20 mg of melatonin daily for two months did not reduce pelvic pain (Soderman, PLoS One 2023) [62], while an earlier study of 40 women found 10 mg daily for eight weeks reduced daily pain by 40% and menstrual pain by 38% (Schwertner, Pain 2013) [63].

Dysmenorrhea: A study of 37 women found 10 mg of melatonin taken at night during the menstrual week was not superior to placebo for severe menstrual pain (Soderman, Eur J Clin Pharm 2021) [64].

Cancer Treatment Support

Breast cancer: A study of 36 women undergoing chemotherapy found that 20 mg of melatonin nightly for 10 days beginning 3 days before the first session modestly improved sleep quality, depression symptoms, and some cognitive measures compared to placebo (Palmer, PLoS One 2020) [65]. A study using 6 mg nightly after breast cancer surgery found 4% greater sleep efficiency and 37 minutes more sleep per night, with notably lower dropout rates (1/28 vs. 10/26 with placebo) (Hansen, Intl J Breast Cancer 2014) [66]. However, a study of 78 patients with early-stage breast cancer found 20 mg of melatonin during radiotherapy did not reduce fatigue, anxiety, depression, sleep difficulties, or other symptoms compared to placebo (Mukhopadhyay, Oncologist 2023) [67].

Lung cancer (NSCLC): A study of 67 patients receiving chemotherapy for advanced NSCLC found that 20 mg of melatonin taken at 8 PM was associated with greater overall survival, particularly in those with normal baseline sleep quality (17.6 vs. 10.4 months). Melatonin taken in the morning (8 AM) did not improve survival. All melatonin users had improvements in shortness of breath at 3 months (Grutsch, Biol Rhythm Res 2021) [68].

Multiple Sclerosis

Mixed results. A study of 23 MS patients found that 3 mg or 5 mg of melatonin nightly for one year did not improve MS functioning, reduce fatigue, or improve sleep quality or quality of life (Smoot, Mult Scler Relat Disord 2024) [69]. However, a placebo-controlled study of 27 adults with relapsing-remitting MS found that 3 mg of melatonin for 12 weeks significantly increased total sleep time (32%), sleep efficiency (8%), and sleep quality (48%), while reducing sleep latency (38%) and nighttime awakenings (36%) (Jallouli, Metab Brain Dis 2024) [70]. A smaller study found a single 6 mg dose improved sleep quality by 32% and improved balance and functional performance the following morning (Jallouli, Int J Neurosci 2022) [71].

Gastrointestinal Conditions

Irritable bowel syndrome (IBS): Several small studies suggest 3 mg of melatonin at bedtime may reduce IBS symptoms without improving sleep. One study among women with IBS found reduced abdominal distension and pain compared to placebo but no changes in stool consistency or sleep (Lu, Aliment Pharmacol Ther 2005) [72]. Another study found 45% vs. 17% improvement in overall IBS scores and 44% vs. 15% improvement in quality of life (Saha, J Clin Gastroenterol 2007) [73]. A third found significant reductions in abdominal pain scores (2.35 vs. 0.70) (Song, Gut 2005) [74]. Pediatric experts do not recommend melatonin for IBS in children (Groen, J Pediatr Gastroenterol Nutr 2025) [75].

Gastric ulcers: Among people with H. pylori infection, those who are symptomatic have lower nighttime melatonin levels (Wilhelmsen, J Pineal Res 2011) [76]. One study found that 5 mg of melatonin twice daily along with triple therapy healed ulcers in 100% of patients by week 3 vs. 50% with triple therapy alone (Celinski, J Physiol Pharmacol 2011) [77].

GERD: Preliminary studies suggest melatonin may reduce GERD symptoms, particularly when combined with a proton-pump inhibitor. A study of 72 people found that 3 mg of sublingual melatonin before bed plus omeprazole reduced heartburn in 87% vs. 58% with omeprazole plus placebo (Malekpour, Turk J Gastroenterol 2023) [78]. An earlier study using 6 mg of melatonin in a formula with L-tryptophan and B vitamins reported 100% symptom regression after 40 days vs. 65.7% with omeprazole, though this study was not double-blind (Pereira, J Pineal Res 2006) [79].

Functional dyspepsia: A study of adults found 5 mg at bedtime for 12 weeks resolved epigastric pain in 56.6% vs. 6.7% with placebo (Klupinksa, J Clin Gastroent 2007) [80], though a study in children (ages 8-17) found 5 mg daily for 2 weeks was no better than placebo (Zybach, World J Gastro Pharm Ther 2016) [81].

Skin Conditions

Atopic dermatitis: A placebo-controlled study in children and adolescents found that 3 mg of melatonin at bedtime for 4 weeks resulted in about 20% reduction in symptoms and a 21.4-minute decrease in time to fall asleep, with no adverse effects (Chang, JAMA Pediatr 2016) [82].

Melasma: A study of 47 women found 5 mg of melatonin before bedtime for 8 weeks decreased melasma severity by 22% vs. 12% with placebo. The difference was statistically significant but clinically minor (Holanda, JEADV 2024) [83].

Pain Conditions

Fibromyalgia: A study found that increasing doses (3-15 mg) taken 30 minutes before bed for 10 days each showed that pain reductions became statistically significant at 9 mg and higher, and improvements in anxiety and mood were significant at 12-15 mg (Castrano, Biol Res Nurs 2018) [84].

Neuropathic pain: A study of 30 adults with various types of nerve pain found that 3-12 mg of melatonin nightly (escalating dose over 4 weeks) did not significantly reduce average daily pain compared to placebo (Gilron, Pain 2025) [85].

Beta-Blocker-Induced Sleep Disturbance

Beta-blockers can suppress endogenous melatonin production. A study found that 2.5 mg of melatonin taken one hour before bedtime for three weeks decreased time to fall asleep by 8 minutes and increased total sleep time by 37 minutes in patients taking atenolol or metoprolol, with no adverse effects (Sheer, Sleep 2012) [10].

Cognitive Function and Dementia

Melatonin does not appear to improve cognitive function or memory in healthy older adults (Otmani, Hum Psychopharmacol 2008) [86]. People with Alzheimer's disease have lower nighttime melatonin in blood and cerebrospinal fluid, but an analysis of 7 clinical studies found that 2-3 mg at bedtime for at least 12 weeks showed only limited areas of improvement and no overall benefit on cognitive assessment (ADAS-Cog scale) (Sumsuzzman, Neurosci Biobehav Rev 2021) [87]. A study of 38 adults with mild cognitive impairment found 25 mg of immediate-release melatonin for 12 weeks did not improve cognition or sleep (Schrire, J Pineal Res 2024) [88]. The American Academy of Sleep Medicine recommends against melatonin use in people with dementia [13][22].

Age-Related Macular Degeneration (AMD)

A review of medical records of over 120,000 people aged 50+ found melatonin use was associated with a 58% reduction in risk of developing AMD and 56% reduction in AMD progression compared to non-users (Jeong, JAMA Ophthalmol 2024) [89]. This is an observational association and does not prove causation. A small study of 55 adults with AMD given 3 mg nightly found none showed visual acuity deterioration after 6 months, but there was no placebo control (Yi, Ann N Y Acad Sci 2005) [90].

COVID-19

Prevention: Despite an observational study linking melatonin use with lower COVID-19 test positivity, a clinical study of 314 healthcare workers found 2 mg of melatonin for 12 weeks did not reduce COVID-19 cases compared to placebo -- in fact, 5.5% of the melatonin group tested positive vs. 2.6% of placebo (Garcia-Garcia, J Clin Med 2022) [91].

Treatment: Mixed results. A study of 98 adults found that 10 mg of melatonin for 14 days improved quality of life during peak illness (days 3-9) but not over the full 14 days (Fogleman, J Am Board Fam Med 2022) [92]. A study of 791 ventilated patients found melatonin use was associated with 13% lower mortality risk (Ramlall, medRxiv 2020) [93]. A study in Iran found melatonin (3 mg three times daily for 2 weeks) shortened hospitalization (4.65 vs. 8.15 days) and reduced symptoms (Farnoosh, Authorea Preprints 2020) [94]. However, a study in France found no difference in mortality with melatonin (average daily dose 2.61 mg) (Sanchez-Rico, J Travel Med 2022) [95].

Recommended Dosing

General Principles

Melatonin is a hormone, and the lowest effective dose should be tried first. Doses as low as 0.1-0.3 mg can increase blood concentrations to the range normally found at night in young adults [1][13]. Higher doses (1-5 mg) in children can achieve melatonin levels 5-25 times higher than normal nighttime ranges, and the long-term safety of this is unknown [96].

Dosing by Indication

Indication	Dose	Timing	Duration
General sleep onset	0.5-3 mg (start low)	30-60 min before bedtime	As needed
Jet lag	2-3 mg	Bedtime at destination	4 days post-travel
Delayed sleep phase syndrome	0.5 mg	1 hour before desired bedtime	4+ weeks
Delayed weekend sleep pattern	6 mg	5 hours before desired Sunday bedtime	As needed
Children with chronic insomnia	1-3 mg (start with 0.5-1 mg)	6-7 PM	Under medical supervision
Children with ASD/developmental disorders	1-5 mg (start with 1 mg)	30-60 min before bedtime	Under medical supervision
Preoperative anxiety	3-10 mg	1-1.5 hours before procedure	Single dose
Migraine prevention	3 mg	Daily	3 months
Cluster headache prevention	10 mg	Before bedtime	Daily
IBS symptoms	3 mg	Bedtime	Daily
Beta-blocker sleep disturbance	2.5 mg	1 hour before bedtime	3 weeks
Cancer treatment adjunct	10-50 mg	Daily prior to and during therapy	Variable

How and When to Take

Take regular tablets, capsules, and softgels 30-60 minutes before desired sleep time. Liquids and fast-dissolving tablets can be taken approximately 20 minutes before sleep. For conditions involving circadian rhythm shifting (DSPS), timing relative to the circadian phase is more important than the dose [1].

Melatonin can be taken with or without food. Splitting between immediate-release (2-3 mg) and sustained-release (3 mg) forms may help with both sleep onset and sleep maintenance [1].

Product Mention

Dr Brad Stanfield's Sleep by Dr Brad combines a micro-dose of melatonin (0.3 mg -- within the physiological range that restores nighttime levels without the grogginess and receptor desensitization associated with standard 3-5 mg doses) with magnesium glycinate and glycine (2,500 mg), which work through complementary mechanisms: melatonin signals circadian sleep onset, magnesium promotes relaxation via GABA receptor activation, and glycine lowers core body temperature at bedtime.

Safety and Side Effects

Common Side Effects

A review of clinical studies found the most commonly reported adverse effects [97]:

• Drowsiness: 20.3%
• Headache: 7.8%
• Dizziness: 4.0%
• Nausea: 1.5%

Other reported side effects include mild abdominal pain, cramps, and diarrhea (Van der Heijden, J Am Acad Child Adolesc Psychiatry 2007) [98]. There is one report of melatonin triggering Crohn's disease symptoms (cramps and diarrhea) in a 35-year-old woman who took 3 mg for four days; symptoms resolved within one day of stopping (Calvo, J Pineal Res 2002) [99].

Balance and Driving

Drowsiness and impaired balance may occur for up to six hours after taking melatonin. A study of adults ages 60-71 found that a single 3 mg dose significantly impaired balance one hour after taking, though it did not affect cognitive function (Lui, J Aging Phys Act 2018) [100]. Do not drive or operate heavy machinery during this period.

Higher-dose controlled-release products may cause next-day drowsiness. A study found a 4 mg product (3 mg controlled-release + 1 mg immediate-release) resulted in high melatonin levels for 10 hours, while a 0.4 mg product maintained levels for only 6.4 hours (Gooneratne, J Pineal Res 2012) [101]. Standard-release products at low doses do not appear to cause a "hangover" effect.

Interactions with Sleep Medications

Melatonin taken with the hypnotic drug zolpidem (Ambien) increased zolpidem's effects on cognitive and driving performance at 4 hours and impaired memory recall at 12.5 hours (Otmani, Hum Psychopharmacol 2008) [86]. A "hangover" effect has also been reported when melatonin is combined with eszopiclone (Lunesta) (Victor, Medicines 2023) [102]. Side effects were not reported in short-term studies combining melatonin with benzodiazepines (lorazepam, alprazolam) [103][104].

Fracture Risk

Long-term melatonin use has been associated with increased fracture risk. A UK study found that adults (average age 65) prescribed melatonin were 90% more likely to have suffered a fracture than matched controls, with risk remaining 44% elevated after adjusting for confounders. Only patients with three or more prescriptions had elevated risk (Frisher, Age and Ageing 2016) [105]. Although melatonin increases bone density (see Section 3), it may do so by inhibiting bone resorption rather than promoting bone formation -- and bone resorption is essential for fracture healing. A mouse study found that high-dose melatonin impaired fracture healing (Histing, J Surg Res 2012) [106].

Cardiovascular Concerns

Use of melatonin for one year or more was associated with an 89% greater risk of heart failure, a three-fold increase in heart-failure-related hospitalizations, and doubling of deaths over 5 years compared to non-users in an analysis of 130,828 people. This was presented at an American Heart Association meeting (AHA 2025) but has not been published in a peer-reviewed journal and does not prove causation [107].

Rarely, heart palpitations or premature ventricular contractions (PVCs) have been associated with melatonin use at 1-8 mg, typically in people with a history of heart rhythm conditions. In two case reports, PVCs associated with daily 1 mg melatonin resolved months after discontinuation (de Vries, J Cardiovasc Pharmacol 2017) [108].

Blood Pressure Effects

Melatonin may decrease blood pressure in healthy normotensive people [109]. Conversely, in people taking the calcium channel blocker nifedipine GITS, 5 mg of immediate-release melatonin at bedtime increased systolic blood pressure by 6.5 mmHg and diastolic by 4.9 mmHg (Lusardi, Br J Clin Pharmacol 2000) [110].

Blood Sugar and Diabetes

Melatonin may worsen blood sugar control in type 2 diabetes. A study of 30 diabetic patients found that 3 mg of melatonin at night increased glycemic variability following breakfast by approximately 36% compared to placebo (Martorina, Nutrients 2023) [111]. A study of non-diabetic women found 5 mg of melatonin impaired glucose tolerance by decreasing insulin release in the morning and insulin sensitivity at night (Rubio-Sastre, Sleep 2014) [112]. People with diabetes or taking antidiabetic medications should use caution [1].

Hormonal Effects

Testosterone and estrogen metabolism may be affected; very high doses (over 75 mg daily) might prevent ovulation in women. In women entering menopause, melatonin may cause resumption of menstrual flow or spotting. Oral contraceptives may increase melatonin absorption in some people (Hilli, J Clin Pharmacol 2008) [113].

Melatonin may stimulate growth hormone secretion. A case report described a 34-year-old woman who developed elevated growth hormone (10.9 vs. normal 0.01-3.6 mcg/L) and IGF-1 after taking 2 mg nightly for 3 months; levels normalized one month after stopping (Di Vincenzo, JCEM Case Rep 2025) [114].

Restless Legs Syndrome

Melatonin may increase leg movements in RLS. A study found significantly more leg movement 1 hour and 4.5 hours after 3 mg of melatonin in people with severe RLS, though patients did not report increased discomfort (Whittom, Sleep Med 2010) [115].

Aggression

A study of male college students found that 5 mg of melatonin increased reactive aggression -- participants selected high punishments 57.3% of the time vs. 41.5% with placebo during a game experiment (Liu, Psychopharm 2017) [116].

Vivid Dreams

Some people report more vivid dreams when using melatonin [1].

Mental Health

Extremely high doses (250-1,200 mg) have been reported to worsen depression and cause hallucinations, rage, and terror in people with depression and bipolar disorder (Carman, Am J Psychiatry 1976) [117]. However, typical doses (less than 10 mg) for up to 3.5 years have not been reported to cause or worsen depression (Hansen, Eur Neuropsychopharmacol 2014) [118].

Seizures

Evidence is mixed. Some studies found melatonin decreased seizures or improved sleep in children (Chen, J Formos Med Assoc 2012) [119], while others reported increased seizure activity in neurologically disabled children with severe sleep complaints (Sheldon, Lancet 1998) [120]. Consult a physician before taking melatonin with seizure disorders.

Asthma

Concern was raised that melatonin might worsen nighttime asthma, but a study found that 3 mg nightly for about one month did not significantly affect lung function in people with mild to moderate stable asthma (Campos, Am J Respir Crit Care Med 2004) [121]. Animal research suggests that higher doses may promote airway constriction and reduce the relaxant effects of bronchodilators (Sasaki, Am J Physiol Lung Cell Mol Physiol 2021) [122].

Pregnancy and Lactation

Safety in pregnant or breastfeeding women has not been established [1][13]. A study of 109 pregnant women undergoing labor induction found that up to 40 mg of melatonin over 24 hours did not improve labor outcomes and more infants in the melatonin group required special care nursery admission for blood sugar monitoring (18.5% vs. 8.1%) (Quach, Acta Obstet Gynecol Scand 2024) [123].

Children -- Poison Control Concerns

Reports to US poison control centers due to melatonin ingestion by those 19 and younger increased 530% from 2012 to 2021. Although 82.8% were asymptomatic, 10.7% received healthcare facility care, five children required mechanical ventilation, and two infants died. The sharpest increase coincided with the COVID-19 pandemic. Experts recommend child-resistant packaging (Lelak, MMWR 2022) [124]. A 2023 study found 22/25 melatonin gummy products were inaccurately labeled, with levels ranging from 74% to 347% of the labeled quantity [13].

Label Accuracy Concerns

The 2023 study testing 25 melatonin gummy products found most contained more melatonin than labeled (majority 1.2-1.7 times more), and 26% of tested supplements in an earlier study contained serotonin, a hormone that can have harmful effects at relatively low levels [13][125].

Drug Interactions

Medication	Interaction	Notes
Fluvoxamine (Luvox)	Significantly increases melatonin absorption via CYP1A2 inhibition	Increased risk of drowsiness and other side effects (Harter, Clin Pharmacol Ther 2000) [126]
Caffeine	CYP1A2 inhibition increases melatonin levels	Consuming caffeine with melatonin may significantly increase melatonin levels (Harpsoe, Eur J Clin Pharmacol 2015) [127]. Paradoxically, afternoon/evening coffee may decrease endogenous melatonin [11]
Oral contraceptives	May increase melatonin absorption	(Hilli, J Clin Pharmacol 2008) [113]
Nifedipine (Procardia XL)	Melatonin may increase blood pressure	5 mg increased SBP by 6.5 mmHg and DBP by 4.9 mmHg (Lusardi, Br J Clin Pharmacol 2000) [110]
Warfarin, clopidogrel, rivaroxaban	Melatonin may decrease blood clotting	Isolated reports of bleeding; use with caution (Wirtz, J Pineal Res 2008) [128]
Aspirin, NSAIDs (ibuprofen, diclofenac)	Potential additive anticoagulant effect	Use with caution [1]
Zolpidem (Ambien)	Enhanced cognitive/driving impairment	Effects observed at 4 hours post-dose (Otmani, Hum Psychopharmacol 2008) [86]
Eszopiclone (Lunesta)	"Hangover" effect next day	(Victor, Medicines 2023) [102]
Benzodiazepines (lorazepam, alprazolam)	Potential increased sedation	Short-term studies did not report side effects, but long-term data lacking [103][104]
Beta-blockers (atenolol, metoprolol)	Beta-blockers suppress endogenous melatonin; supplementation may help sleep	2.5 mg melatonin improved sleep in beta-blocker users [10]
Antiseizure medications	Potential interaction with seizure threshold	Consult physician (phenobarbital, gabapentin, carbamazepine, phenytoin) [119][120]
Antidiabetic medications	Melatonin may worsen blood sugar control	Use caution with insulin, glimepiride, glyburide, pioglitazone, rosiglitazone [1][111]
Immunosuppressants	Melatonin may stimulate immune function	May theoretically counteract immunosuppressive therapy [7]
Antipsychotics (risperidone)	Enhanced sedative effects	Monitor for increased drowsiness, dizziness, confusion [129]

Dietary Sources

Melatonin occurs naturally in many foods, but in extremely small amounts compared to supplemental doses. Average dietary melatonin intake among adults has been estimated at only about 0.026 mg per day -- well below typical therapeutic doses of 0.3-10 mg (Zanirate, J Hum Nutr Diet 2026) [130].

Food Sources

Food	Melatonin Content	Notes
Pistachios (raw)	~0.00001 mg/g (~4 nuts)	Highest among common raw nuts
Chestnuts, almonds, pine nuts	Slightly higher than pistachios	Still minute amounts
Tart cherries	~0.000013 mg/g	Very small amounts
Coffee	Trace amounts	Contributes to dietary intake
Beans/lentils	Trace amounts
Rice	Trace amounts
Brazil nuts, cashews, hazelnuts, peanuts	Lower than pistachios	Roasting increases melatonin in peanuts, decreases in all other nuts

Source: Verde, J Food Compost Anal 2021 [131]; Meng, Nutrients 2017 [132].

Nuts are sometimes promoted as a meaningful source of melatonin, but the amounts are far too small to provide therapeutic effects. An earlier study from Iran (Oladi, 2014) suggested much higher melatonin content in pistachios (0.23 mg/g), but the unusual extraction method and suspiciously uniform results raised concerns about reliability (Nawaz, Front Plant Sci 2016) [133].

Tart cherry products are marketed for sleep, but their melatonin content is minimal. Any sleep benefits from tart cherry juice are more likely attributable to other compounds (such as procyanidins that inhibit tryptophan degradation) rather than their melatonin content [132].

References

[1] ConsumerLab. "Melatonin Supplements Review." https://www.consumerlab.com/reviews/melatonin-supplements/melatonin/

[2] Tordjman S, Chokron S, Delorme R, et al. "Melatonin: pharmacology, functions and therapeutic benefits." *Curr Neuropharmacol*. 2017;15(3):434-443. doi: 10.2174/1570159X14666161228122115

[3] Masters A, Pandi-Perumal SR, Seixas A, et al. "Melatonin, the Hormone of Darkness: From Sleep Promotion to Ebola Treatment." *Brain Disord Ther*. 2014;4(1):1000151. doi: 10.4172/2168-975X.1000151

[4] Posadzki P, Bajpai R, Kyaw BM, et al. "Melatonin and health: an umbrella review of health outcomes and biological mechanisms of action." *BMC Med*. 2018;16(1):18. doi: 10.1186/s12916-017-0995-7

[5] Reiter RJ, Rosales-Corral SA, Tan D-X, et al. "Melatonin, a full service anti-cancer agent: inhibition of initiation, progression and metastasis." *Int J Mol Sci*. 2017;18(4):E843. doi: 10.3390/ijms18040843

[6] Carillo-Vico A, et al. "Melatonin: buffering the immune system." *Int J Mol Sci*. 2013. doi: 10.3390/ijms14048638

[7] Miller SC, et al. "The role of melatonin in immuno-enhancement: potential application in cancer." *Int J Exp Pathol*. 2006;87(2):81-87. doi: 10.1111/j.0959-9673.2006.00474.x

[8] Gooley JJ, et al. "Exposure to room light before bedtime suppresses melatonin onset and shortens melatonin duration in humans." *J Clin Endocrinol Metab*. 2011;96(3):E463-E472. doi: 10.1210/jc.2010-2098

[9] Djeridane Y, et al. "Influence of diazepam on melatonin secretion." *Psychopharmacology (Berl)*. 2001.

[10] Sheer FAJL, et al. "Melatonin improves sleep in patients taking beta-blockers." *Sleep*. 2012.

[11] Shilo L, et al. "The effects of coffee consumption on sleep and melatonin secretion." *Sleep Med*. 2002;3(3):271-273.

[12] Nishi T, et al. "Cataract surgery and melatonin production." *JAMA Ophthalmol*. 2020.

[13] National Center for Complementary and Integrative Health (NCCIH). "Melatonin: What You Need to Know." Updated May 2024. https://www.nccih.nih.gov/health/melatonin-what-you-need-to-know

[14] Matsumoto M, et al. "Short-term melatonin supplementation does not affect endogenous melatonin production." *J Pineal Res*. 1997.

[15] Lemoine P, et al. "Prolonged-release melatonin does not cause rebound insomnia or withdrawal." *Ther Clin Risk Manag*. 2011.

[16] Zetner D, et al. "Pharmacokinetics of alternative administration routes of melatonin: a systematic review." *Drug Res (Stuttg)*. 2016.

[17] Di WL, et al. "Melatonin pharmacokinetics." *N Engl J Med*. 1997.

[18] DeMuro RL, et al. "Pharmacokinetics of oral melatonin." *J Clin Pharmacol*. 2000.

[19] Andersen LP, et al. "Pharmacokinetics of oral and intravenous melatonin." *BMC Pharmacol Toxicol*. 2016.

[20] Kukula-Koch W, et al. "Comparative antioxidant and anti-inflammatory activity of phytomelatonin vs. synthetic melatonin." *Molecules*. 2021.

[21] Ponce S, et al. "Topical melatonin lotion and sleep quality." *Neuro Endocrinol Lett*. 2024.

[22] Sateia MJ, Buysse DJ, Krystal AD, et al. "Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults." *J Clin Sleep Med*. 2017;13(2):307-349. doi: 10.5664/jcsm.6470

[23] Xu M, et al. "Melatonin for primary insomnia." *Sleep Med*. 2020.

[24] Motlaq TA, et al. "Melatonin for obstructive sleep apnea with insomnia." *J Pharm Health Care Sci*. 2024.

[25] Jun JS, et al. "Prolonged-release melatonin for REM sleep behavior disorder." *Ann Clin Transl Neurol*. 2019.

[26] Ahn JH, et al. "Prolonged-release melatonin and Parkinson's disease sleep quality." *Parkinsonism Relat Disord*. 2020.

[27] Mack J, et al. "Melatonin in Parkinson's disease: benefits and risks." *Oxid Med Cell Longev*. 2017.

[28] Medeiros CA, et al. "Effect of melatonin on sleep in Parkinson's disease." *J Neurol*. 2007.

[29] Lopez-Gonzalez MA, et al. "Sulpiride and melatonin for tinnitus." *J Otolaryngol*. 2007.

[30] Tunkel DE, et al. "Clinical practice guideline: tinnitus." *Otolaryngol Head Neck Surg*. 2014.

[31] Nogueira PSF, et al. "Melatonin and sleep in glaucoma." *Ophthalmol Glaucoma*. 2025.

[32] Braam W, et al. "Loss of response to melatonin and dose reduction." *J Intellect Disabil Res*. 2010.

[33] Sletten TL, Magee M, Murray JM, et al. "Efficacy of melatonin with behavioural sleep-wake scheduling for delayed sleep-wake phase disorder." *PLoS Med*. 2018;15(6):e1002587. doi: 10.1371/journal.pmed.1002587

[34] Herxheimer A. "Jet lag." *Clin Evidence*. 2014;2014:2303.

[35] Liira J, Verbeek JH, Costa G, et al. "Pharmacological interventions for sleepiness and sleep disturbances caused by shift work." *Cochrane Database Syst Rev*. 2014;(8):CD009776.

[36] Thottakam B, et al. "Slow-release melatonin and shift work performance." *Front Psychiatry*. 2020.

[37] Marqueze EC, et al. "Melatonin, circadian rhythm, and night shift nurses." *J Pineal Res*. 2021.

[38] American Academy of Sleep Medicine. "Statement on melatonin use in children." 2022.

[39] van Maanen A, et al. "Melatonin for chronic sleep onset insomnia in children." *Sleep*. 2017.

[40] Gringras P, et al. "Prolonged-release melatonin for insomnia in children with ASD." *J Am Acad Child Adolesc Psychiatry*. 2017. doi: 10.1016/j.jaac.2017.09.414

[41] Malow BA, et al. "Long-term safety of prolonged-release melatonin in children with ASD." *J Am Acad Child Adolesc Psychiatry*. 2020.

[42] Hayashi M, et al. "Melatonin for sleep onset in children with ASD in Japan." *J Autism Dev Disord*. 2021.

[43] Tse ACY, et al. "Melatonin and exercise for sleep in children with ASD." *J Autism Dev Disord*. 2023.

[44] McDonagh MS, et al. "Pharmacologic treatments for sleep disorders in children." *J Child Neurol*. 2019;34(5):237-247. doi: 10.1177/0883073818821030

[45] Madsen BK, et al. "Melatonin for preoperative and postoperative anxiety in adults." *Cochrane Database Syst Rev*. 2020.

[46] Marseglia L, et al. "Melatonin and preoperative anxiety in children." *J Biol Regul Homeost Agents*. 2015.

[47] Gandolfi JV, et al. "Melatonin for ICU sleep quality." *Crit Care Med*. 2020.

[48] Perez JR, et al. "Melatonin after rotator cuff repair." *Am J Sports Med*. 2024.

[49] Clarkson K, et al. "Melatonin after hip or knee replacement." *J Am Acad Orthop Surg*. 2021.

[50] Haider MN, et al. "Melatonin after total knee replacement." *J Arthroplasty*. 2024.

[51] Ford AH, et al. "Melatonin and post-operative delirium after cardiac surgery." *J Am Geriatr Soc*. 2019.

[52] Mengel A, et al. "Melatonin and post-stroke delirium." *Eur J Neurol*. 2021.

[53] Goncalves AL, et al. "Melatonin vs. amitriptyline for migraine prevention." *J Neurol Neurosurg Psychiatry*. 2016. doi: 10.1136/jnnp-2016-313458

[54] Rozen TD. "Melatonin for primary stabbing headache." *Neurology*. 2003.

[55] Salazar LA, et al. "Melatonin for primary stabbing headache in a child." *Colomb Med (Cali)*. 2018.

[56] Zhang Y, et al. "Melatonin and perimenopausal symptoms." *J Healthc Eng*. 2023.

[57] Chojnacki C, et al. "Melatonin and postmenopausal symptoms over one year." *J Physiol Pharmacol*. 2018.

[58] Saraiva MV, et al. "Low-dose melatonin in menopause." *J Pineal Res*. 2026.

[59] Leerasiri P, et al. "Melatonin and nocturia in postmenopausal women." *Int Urogynecol J*. 2022.

[60] Amstrup AK, et al. "Melatonin, bone density, and postmenopausal women." *J Pineal Res*. 2015.

[61] Jamilian M, et al. "Melatonin for PCOS." *Front Endocrin*. 2019.

[62] Soderman L, et al. "Melatonin and endometriosis pain (negative result)." *PLoS One*. 2023.

[63] Schwertner A, et al. "Melatonin and endometriosis pain (positive result)." *Pain*. 2013.

[64] Soderman L, et al. "Melatonin and dysmenorrhea." *Eur J Clin Pharm*. 2021.

[65] Palmer ACS, et al. "Melatonin during breast cancer chemotherapy." *PLoS One*. 2020.

[66] Hansen MV, et al. "Melatonin after breast cancer surgery." *Intl J Breast Cancer*. 2014.

[67] Mukhopadhyay A, et al. "Melatonin during breast cancer radiotherapy." *Oncologist*. 2023.

[68] Grutsch JF, et al. "Melatonin and survival in advanced NSCLC." *Biol Rhythm Res*. 2021.

[69] Smoot K, et al. "Melatonin in relapsing MS (one-year, no benefit)." *Mult Scler Relat Disord*. 2024.

[70] Jallouli S, et al. "Melatonin and sleep in relapsing-remitting MS (12 weeks, benefit)." *Metab Brain Dis*. 2024.

[71] Jallouli S, et al. "Single-dose melatonin in relapsing-remitting MS." *Int J Neurosci*. 2022.

[72] Lu WZ, et al. "Melatonin for IBS in women." *Aliment Pharmacol Ther*. 2005.

[73] Saha L, et al. "Melatonin for IBS." *J Clin Gastroenterol*. 2007.

[74] Song GH, et al. "Melatonin and IBS abdominal pain." *Gut*. 2005.

[75] Groen RN, et al. "Melatonin not recommended for IBS in children." *J Pediatr Gastroenterol Nutr*. 2025.

[76] Wilhelmsen M, et al. "H. pylori and melatonin levels." *J Pineal Res*. 2011.

[77] Celinski K, et al. "Melatonin as adjunct therapy for gastric ulcers." *J Physiol Pharmacol*. 2011.

[78] Malekpour A, et al. "Melatonin plus omeprazole for GERD." *Turk J Gastroenterol*. 2023.

[79] Pereira RS, et al. "Melatonin-tryptophan formula for GERD." *J Pineal Res*. 2006.

[80] Klupinksa G, et al. "Melatonin for functional dyspepsia." *J Clin Gastroent*. 2007.

[81] Zybach K, et al. "Melatonin for functional dyspepsia in children." *World J Gastro Pharm Ther*. 2016.

[82] Chang YS, et al. "Melatonin for atopic dermatitis in children." *JAMA Pediatr*. 2016. doi: 10.1001/jamapediatrics.2015.3092

[83] Holanda CSM, et al. "Melatonin for melasma." *JEADV*. 2024.

[84] Castrano MYB, et al. "Melatonin dose-response in fibromyalgia." *Biol Res Nurs*. 2018.

[85] Gilron I, et al. "Melatonin for neuropathic pain." *Pain*. 2025.

[86] Otmani S, et al. "Effects of melatonin and zolpidem on cognition, driving, and memory." *Hum Psychopharmacol*. 2008.

[87] Sumsuzzman DM, et al. "Melatonin in Alzheimer's disease: a meta-analysis." *Neurosci Biobehav Rev*. 2021.

[88] Schrire ZM, et al. "Melatonin for mild cognitive impairment." *J Pineal Res*. 2024.

[89] Jeong J, et al. "Melatonin use and age-related macular degeneration." *JAMA Ophthalmol*. 2024.

[90] Yi C, et al. "Melatonin and AMD." *Ann N Y Acad Sci*. 2005.

[91] Garcia-Garcia I, et al. "Melatonin for COVID-19 prophylaxis." *J Clin Med*. 2022.

[92] Fogleman CD, et al. "Melatonin for COVID-19 symptoms." *J Am Board Fam Med*. 2022.

[93] Ramlall V, et al. "Melatonin and mortality in COVID-19." *medRxiv*. 2020.

[94] Farnoosh G, et al. "Melatonin and COVID-19 hospitalization." *Authorea Preprints*. 2020.

[95] Sanchez-Rico M, et al. "Melatonin and COVID-19 mortality (no benefit)." *J Travel Med*. 2022.

[96] Abramowicz M, et al. "Melatonin in children: dosing considerations." *JAMA*. 2020.

[97] Buscemi N, et al. "Melatonin adverse effects review." *AHRQ*. 2004.

[98] Van der Heijden KB, et al. "Melatonin side effects in children." *J Am Acad Child Adolesc Psychiatry*. 2007.

[99] Calvo JR, et al. "Melatonin triggering Crohn's symptoms." *J Pineal Res*. 2002.

[100] Lui GY, et al. "Melatonin and balance in older adults." *J Aging Phys Act*. 2018.

[101] Gooneratne NS, et al. "Melatonin product dissolution and blood levels." *J Pineal Res*. 2012.

[102] Victor LD, et al. "Melatonin and eszopiclone interaction." *Medicines*. 2023.

[103] Garfinkle D, et al. "Melatonin facilitating benzodiazepine discontinuation." *JAMA*. 1999.

[104] Cardinali DP, et al. "Melatonin and benzodiazepine use in older adults." *Neuro Endocrinol Lett*. 2002.

[105] Frisher M, et al. "Melatonin and fracture risk." *Age and Ageing*. 2016.

[106] Histing T, et al. "Melatonin and fracture healing in mice." *J Surg Res*. 2012.

[107] American Heart Association meeting presentation. "Melatonin and heart failure risk." AHA 2025 (not peer-reviewed).

[108] de Vries JJ, et al. "PVCs associated with melatonin." *J Cardiovasc Pharmacol*. 2017.

[109] Arangino S, et al. "Melatonin decreases blood pressure in normotensive subjects." *Am J Cardiol*. 1999.

[110] Lusardi P, et al. "Melatonin and nifedipine blood pressure interaction." *Br J Clin Pharmacol*. 2000.

[111] Martorina WJ, et al. "Melatonin and glycemic variability in diabetes." *Nutrients*. 2023.

[112] Rubio-Sastre P, et al. "Melatonin and glucose tolerance." *Sleep*. 2014.

[113] Hilli J, et al. "Oral contraceptives and melatonin absorption." *J Clin Pharmacol*. 2008.

[114] Di Vincenzo M, et al. "Melatonin-induced growth hormone elevation." *JCEM Case Rep*. 2025.

[115] Whittom S, et al. "Melatonin and leg movements in RLS." *Sleep Med*. 2010.

[116] Liu J, et al. "Melatonin and reactive aggression." *Psychopharm*. 2017.

[117] Carman JS, et al. "High-dose melatonin and depression." *Am J Psychiatry*. 1976.

[118] Hansen MV, et al. "Typical-dose melatonin does not worsen depression." *Eur Neuropsychopharmacol*. 2014.

[119] Chen HJ, et al. "Melatonin and seizures in children." *J Formos Med Assoc*. 2012.

[120] Sheldon SH. "Melatonin and seizure activity in neurologically disabled children." *Lancet*. 1998.

[121] Campos FL, et al. "Melatonin and lung function in asthma." *Am J Respir Crit Care Med*. 2004.

[122] Sasaki H, et al. "Melatonin and airway constriction." *Am J Physiol Lung Cell Mol Physiol*. 2021.

[123] Quach J, et al. "Melatonin during labor induction." *Acta Obstet Gynecol Scand*. 2024.

[124] Lelak K, et al. "Pediatric melatonin ingestions -- United States, 2012-2021." *MMWR*. 2022;71(22):725-729. https://www.cdc.gov/mmwr/volumes/71/wr/mm7122a1.htm

[125] Cohen PA, et al. "Quantity of melatonin and CBD in melatonin gummies sold in the US." *JAMA*. 2023;329(16):1401-1402. doi: 10.1001/jama.2023.2296

[126] Harter S, et al. "Fluvoxamine and melatonin pharmacokinetic interaction." *Clin Pharmacol Ther*. 2000.

[127] Harpsoe NG, et al. "Clinical pharmacokinetics of melatonin." *Eur J Clin Pharmacol*. 2015. doi: 10.1007/s00228-015-1873-4

[128] Wirtz PH, et al. "Melatonin and hemostasis." *J Pineal Res*. 2008.

[129] Drugs.com. "Drug Interactions between melatonin and risperidone." https://www.drugs.com/drug-interactions/melatonin-with-risperidone-2733-0-1916-0.html

[130] Zanirate GS, et al. "Dietary melatonin intake estimation." *J Hum Nutr Diet*. 2026.

[131] Verde A, et al. "Melatonin in nuts and the effect of roasting." *J Food Compost Anal*. 2021.

[132] Meng X, et al. "Dietary sources and forms of melatonin." *Nutrients*. 2017.

[133] Nawaz MA, et al. "Concerns about reported pistachio melatonin content." *Front Plant Sci*. 2016.